- Home
- NUVL vs GPK Comparison
NUVL vs GPK Comparison
Compare NUVL & GPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- GPK
- Stock Information
- Founded
- NUVL 2017
- GPK 2007
- Country
- NUVL United States
- GPK United States
- Employees
- NUVL N/A
- GPK 23000
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- GPK Containers/Packaging
- Sector
- NUVL Health Care
- GPK Consumer Discretionary
- Exchange
- NUVL Nasdaq
- GPK Nasdaq
- Market Cap
- NUVL 5.6B
- GPK 6.4B
- IPO Year
- NUVL 2021
- GPK 1992
- Fundamental
- Price
- NUVL $75.00
- GPK $21.14
- Analyst Decision
- NUVL Strong Buy
- GPK Buy
- Analyst Count
- NUVL 8
- GPK 8
- Target Price
- NUVL $115.50
- GPK $28.40
- AVG Volume (30 Days)
- NUVL 452.9K
- GPK 3.2M
- Earning Date
- NUVL 08-07-2025
- GPK 07-29-2025
- Dividend Yield
- NUVL N/A
- GPK 2.08%
- EPS Growth
- NUVL N/A
- GPK N/A
- EPS
- NUVL N/A
- GPK 2.05
- Revenue
- NUVL N/A
- GPK $8,668,000,000.00
- Revenue This Year
- NUVL N/A
- GPK N/A
- Revenue Next Year
- NUVL N/A
- GPK $2.82
- P/E Ratio
- NUVL N/A
- GPK $10.30
- Revenue Growth
- NUVL N/A
- GPK N/A
- 52 Week Low
- NUVL $55.54
- GPK $20.86
- 52 Week High
- NUVL $113.51
- GPK $30.70
- Technical
- Relative Strength Index (RSI)
- NUVL 48.73
- GPK 35.34
- Support Level
- NUVL $76.42
- GPK $20.97
- Resistance Level
- NUVL $78.94
- GPK $21.65
- Average True Range (ATR)
- NUVL 2.71
- GPK 0.48
- MACD
- NUVL -0.34
- GPK -0.04
- Stochastic Oscillator
- NUVL 31.73
- GPK 10.12
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About GPK Graphic Packaging Holding Company
Graphic Packaging Holding Co is a holding company that manufactures and sells a variety of paper-based consumer packaging products through its subsidiaries. The company's reportable segments are; Paperboard Manufacturing, Americas Paperboard Packaging, and Europe Paperboard Packaging. The majority of the revenue is generated from its Americas Paperboard Packaging segment which includes paperboard packaging sold predominantly to consumer packaged goods (CPG) companies and cups, lids and food containers sold to foodservice companies and quick-service restaurants (QSR) serving the food, beverage, and consumer product markets in the Americas. Geographically, the company generates revenue from the Americas, Europe and Asia Pacific regions.